Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tevogen Bio Holdings Inc. - Warrant (NQ:TVGNW)

0.0602 -0.0117 (-16.27%)
Streaming Delayed Price Updated: 1:44 PM EDT, Aug 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 746
Open 0.0602
Bid (Size) 0.0600 (3)
Ask (Size) 0.0700 (1)
Prev. Close 0.0719
Today's Range 0.0602 - 0.0602
52wk Range 0.0099 - 0.1499
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion
From Tevogen Bio Inc
Via GlobeNewswire

Performance

YTD
+0.3%
+0.3%
1 Month
-11.3%
-11.3%
3 Month
+6.0%
+6.0%
6 Month
-24.3%
-24.3%
1 Year
+167.6%
+167.6%

More News

Read More
REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow
From Tevogen Bio Inc
Via GlobeNewswire
REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
From Tevogen Bio Inc
Via GlobeNewswire
REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen.AI Applauds U.S. Government’s AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen’s New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships
From Tevogen Bio Inc
Via GlobeNewswire
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Via Chartmill
There are notable gap-ups and gap-downs in today's session.
Via Chartmill
Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow
From Tevogen Bio Inc
Via GlobeNewswire

Frequently Asked Questions

Is Tevogen Bio Holdings Inc. - Warrant publicly traded?
Yes, Tevogen Bio Holdings Inc. - Warrant is publicly traded.
What exchange does Tevogen Bio Holdings Inc. - Warrant trade on?
Tevogen Bio Holdings Inc. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for Tevogen Bio Holdings Inc. - Warrant?
The ticker symbol for Tevogen Bio Holdings Inc. - Warrant is TVGNW on the Nasdaq Stock Market
What is the current price of Tevogen Bio Holdings Inc. - Warrant?
The current price of Tevogen Bio Holdings Inc. - Warrant is 0.0602
When was Tevogen Bio Holdings Inc. - Warrant last traded?
The last trade of Tevogen Bio Holdings Inc. - Warrant was at 08/14/25 01:44 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.